needed to increase the cure rate. In vitro experiments show strong antiviral effects of fluvastatin against HCV. Aim of the study: To asses the clinical outcome of fluvastatin addition to the standard regimen for treatment of chronic HCV in Egypt. Subjects and Methods: The study included 80 patients with chronic hepatitis C virus infection fulfilled clinical, laboratory and histo-pathological criteria to be ready for interferon therapy, divided into two groups: Group I (n = 40) received standard treatment for HCV (pegylated interferon and ribavirin) and group II (n = 40) received standard treatment plus fluvastatin (80 mg/daily). Before and after 6 months of treatment liver function tests and HCV-RNA were evaluated. Results: Addition of fluvastatin to the standard HCV treatment (pegylated interferon and ribavirin) significantly increased SVR from (55% to 62.5%; P < 0.01) and significantly decreased viral load in relapser patients (P < 0.001). No significant differences and correlations were found between serum levels of LDL-cholesterol and viral load before and after treatment in both groups. Conclusion: Fluvastatin can be used to increase SVR when added to standard treatment (pegylated interferon and ribavirin) of chronic HCV.
OL-003 Genetic changes in the interferon sensitivity determining region of hepatitis C virus during the natural course of chronic hepatitis C 3a may lead to non-response to interferon therapy 
PMAS Arid Agriculture University Rawalpindi, Pakistan
Background: We have found 70% response rate in Pakistan for Genotype-3a patients with combinationtherapy of interferon and ribavirin. There is need to individualize the treatment to minimize the side effects. Methods: For the current study five G3 patients, nonresponder of 24 weeks interferon-alpha-2b plus ribivirin therapy, withalmost equal levels of viremia (1.8×10 7 IU/ml) at the end of treatmentwere selected. Mean viral load at week 36 was 2.6×10 6 IU/ml, atweek 48 raised to 2.0×10 7 IU/ml. All samples were quantified on RotorGene3000™. Interferon sensitivity-determining region (ISDR) innon-structural region-5A was studied to link any genetic changes in virus genomewith therapy esistance. ISDR was amplified using genotype 3aspecific ISDR primers followed by sequencing and bioinformatics tools.
Result: A157bp ISDR product corresponding to 52 aminoacid protein, when compared with responderHCV patient naïve genome [ Objectives: Our aim was to identify the prevalence of hepatitis C virus (HCV) genotype and investigate genetic mutation of HCV 5 non-coding region (5 NCR) sequences in Shandong province of China. Methods: Serum samples from 118 chronic hepatitis C patients hospitalized in Jinan Infectious Disease hospital were collected. Serum samples were amplified from 5 NCR by RT-PCR and PCR products were sequenced by Sangon Biotech (Shanghai) Co., Ltd. Sequences of 5 NCR of the patients were compared with reference HCV strains from Genebank and phylogenetic tree analysis was performed. Results: The cases among genotype 1b, 2a, 1a, 3a, 3b, 6a were 65 (55.1%), 45 (38.1%), 2, 1, 2 and 3, respectively. Sequences of 5 NCR in 42 genotype 1b patients were identical. Compared to reference HCV 1b strains, 23 genotype 1b patients have 1 2 bases mutation with two characteristic nucleotide mutation sites (120 C-T and 204 C-T). The homology of 5 NCR among genotype 2a patients was 97.8%-100% with characteristic nucleotide mutation sites (site 222 C-T and 247 C-T). The homology of genotype 1a, 3a, 3b and 6a with the same genotype HCV stains from Genebank was high, only with 1 3 bases mutation. Conclusions: The predominant genotype of chronic hepatitis C patients in Shandong province is 1b, followed by 2a and a small amount of 1a, 3a, 3b, 6a. Genotype 3a and 6a are not reported before. Sequence of HCV 5 NCR is highly conservative and accords to HCV strains worldwide. Both genotype 1b and 2a have characteristic nucleotide mutations.
OL-005 A higher correlation of HCV core antigen with CD4+ T cell counts in HCV/HIV coinfected patients
